High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. by Anderhub, SJ et al.
 
 
1 
High proliferation rate and a compromised spindle assembly checkpoint 
confers sensitivity to the MPS1 inhibitor BOS172722 in triple negative 
breast cancers 
Simon J Anderhub1§*, Grace Wing-Yan Mak1*, Mark D Gurden2§*, Amir 
Faisal1§*, Konstantinos Drosopoulos2*, Katie Walsh1§, Hannah L Woodward1§, 
Paolo Innocenti1§, Isaac M Westwood1§, Sébastien Naud1§, Angela Hayes1, 
Efthymia Theofani1§, Simone Filosto1§, Harry Saville1, Rosemary Burke1, Rob 
LM van Montfort1, Florence I Raynaud1, Julian Blagg1§, Swen Hoelder1, 
Suzanne A Eccles1§ and Spiros Linardopoulos1,2 
 
1Cancer Research UK Cancer Therapeutics Unit, Division of Cancer 
Therapeutics, The Institute of Cancer Research, London, United Kingdom; 
2The Breast Cancer Toby Robins Research Centre, The Institute of Cancer 
Research, London, United Kingdom 
§Current address: SA: s.anderhub@gmx.de; MDG: m.gurden@imperial.ac.uk; 
AF: Lahore University of Management Sciences, D.H.A. Lahore Cantt. 54792, 
Lahore, Pakistan, amir.faisal@lums.edu.pk; KW: Katie.walsh@pwc.com; 
HLW: hannah.woodward@ucl.ac.uk; PI: p.innocenti@biology.leidenuniv.nl; 
IMW: isaacmarkwestwood@gmail.com; SN: sebastien.naud@bayer.com; ET: 
efthymiatheofani@gmail.com; SF: simone.filosto@tusktherapeutics.com; JB: 
admin@neophore.com; SAE: Suzanne_e53@hotmail.com 
 
* indicates equal contribution 
Corresponding Authors: Spiros Linardopoulos, Team Leader, Cancer 
Research UK, Cancer Therapeutics Unit, The Institute of Cancer Research, 
15 Cotswold Road, Sutton, SM2 5NG and Breast Cancer Now, 237, Fulham 
Road, London, SW3 6JB, UK. TEL: +44 20 7153 5341, EMAIL: 
spiros.linardopoulos@icr.ac.uk 
Running title: MPS1 inhibitor BOS172722 in TNBC 
Keywords: MPS1, Paclitaxel, Synergy, TNBC, Spindle Assembly Checkpoint 
 
 
2 
Abstract  
BOS172722 (CCT289346) is a highly potent, selective and orally bioavailable 
inhibitor of spindle assembly checkpoint kinase MPS1. BOS172722 treatment 
alone induces significant sensitisation to death, particularly in highly 
proliferative triple negative breast cancer (TNBC) cell lines with compromised 
spindle assembly checkpoint activity. BOS172722 synergises with paclitaxel 
to induce gross chromosomal segregation defects caused by MPS1 inhibitor-
mediated abrogation of the mitotic delay induced by paclitaxel treatment. In in 
vivo pharmacodynamic experiments, BOS172722 potently inhibits the spindle 
assembly checkpoint induced by paclitaxel in human tumour xenograft models 
of TNBC, as measured by inhibition of the phosphorylation of histone H3 and 
the phosphorylation of the MPS1 substrate, KNL1.  This mechanistic synergy 
results in significant in vivo efficacy, with robust tumour regressions observed 
for the combination of BOS172722 and paclitaxel versus either agent alone in 
long-term efficacy studies in multiple human tumour xenograft TNBC models, 
including a patient-derived xenograft and a systemic metastasis model. The 
current target indication for BOS172722 is TNBC, based on their high 
sensitivity to MPS1 inhibition, the well-defined clinical patient population with 
high unmet need, and the synergy observed with paclitaxel. 
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Introduction 
The key mechanism ensuring proper chromosome segregation during mitosis 
is the spindle assembly checkpoint (SAC), which monitors the correct bipolar 
attachment and tension of microtubules (MTs). When all microtubules have 
been properly attached to the kinetochores, the cells enter anaphase by 
releasing activators of the anaphase promoting complex/cyclosome (APC/C) 
(1,2). One of the pivotal proteins of the SAC is MPS1 kinase (also known as 
TTK).  MPS1 is vital for the recruitment of kinetochore components, namely a 
complex of MAD2 and MAD1, to unattached kinetochores (3,4) which in turn 
bind and lock the APC/C co-activator cdc20, keeping the APC/C inhibitory 
complex inactive. MPS1 is further essential for sustaining this inhibitory 
complex throughout mitosis (5-7) and for correcting improperly attached 
chromosomes (8). Consequently, if MPS1 is inhibited, the time cells spend in 
mitosis is drastically reduced, resulting in elevated chromosome segregation 
errors and overall aneuploidy reaches detrimental levels (3,6,9,10). Whilst 
most cancers have a high frequency of aneuploidy (11,12) and chromosome 
instability (CIN) is a common feature (13-15), even these cells cannot tolerate 
aneuploidy beyond a certain threshold and increasing CIN has been shown to 
have a negative impact on their overall viability (16-18). Thus, instant 
generation of unsustainable aneuploidy induced by MPS1 inhibition poses an 
attractive area for therapeutic intervention in cancer and several inhibitors 
have been previously reported (19-26). 
Breast cancer comprises distinct subtypes (27-29) with both human epidermal 
growth receptor 2 (HER2) overexpressing and basal-like breast cancer, 
including triple negative breast cancers (TNBC), having a significantly worse 
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prognosis than luminal and normal-like cancers (28,30-32). Within the distinct 
subgroups, TNBCs are associated with the highest proliferation rate and the 
expression of gene signatures associated with the cell cycle (29,33,34). For 
these reasons, antimitotic chemotherapy seems to be a rational option in 
TNBC and we sought to identify synergistic combinations with established 
therapeutics in order to maximize benefit while minimizing the potential for the 
emergence of secondary resistant tumours.  
Material and Methods 
Reagents and Antibodies 
Eribulin was purchased from Eisai Pharmaceuticals, HOECHST33342 and 
DAPI from Life Technologies. All other reagents were obtained from Sigma. 
Cell culture 
Cell lines were purchased from ATCC and DSMZ. In-house authentication of 
cell lines by SNP profiling was carried out and cultured cells were passaged 
for less than 6 months before replacement from early passage frozen stocks. 
Cells were regularly screened for mycoplasma, using a PCR-based assay 
(VenorGem; Minerva Biolabs).  
Cell based assays 
We performed a High Throughput Screen at Horizon Discovery Inc. as 
described below. The endpoint readout of this assay is based upon 
quantitation of ATP as an indicator of viable cells (except when noted in 
Analyzer). Once cells reached expected doubling times, screening begins.  
Cells are equilibrated in assay plates via centrifugation and placed in CO2 
incubators (attached to the Dosing Modules) at 37oC for twenty-four hours 
before treatment.  At the time of treatment, a set of assay plates (which do not 
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receive treatment) are collected and ATP levels are measured by adding 
ATPLite (Perkin Elmer).  These T-zero (T0) plates are read using ultra-
sensitive luminescence on Envision plate readers.  Assay plates are 
incubated with compound (10-point treatment) for 120 hours and are then 
analysed using ATPLite.  All data points are collected via automated 
processes and are subject to quality control. GI50 and Synergy was 
determined using Horizon’s proprietary software, Chalice. Assay plates are 
accepted if they pass the following quality control standards:  relative raw 
values are consistent throughout the entire experiment, Z-factor scores are 
greater than 0.6 and untreated/vehicle controls behave consistently on the 
plate. GI50 determination in Breast Cancer cell lines was carried out in-house 
in 384 (Greiner Bio-One, #781091), as described below. Cells were seeded at 
individual optimal cell densities and drugs added using an Echo liquid handler 
(Labcyte). After 5 days cells were incubated with HOECHST 33342 stain 
(10g/ml) and Propidium iodide (1g/ml) and assays read on a Celigo 
Imaging Cytometer (Nexcelom) using the Dead&Total application. GI50s were 
assessed using GraphPad prism and a sigmoidal fit. For synergy screening in 
breast cancer cell lines, the respective drug concentrations were: 0.001 and 
0.002M Paclitaxel, 0.0001 and 0.0002M eribulin, 0.002 and 0.004M 
doxorubicin and analysis was performed using the “Macsynergy™II” 
spreadsheet. In brief, cells were seeded at optimal densities in 96 well plates. 
BOS172722 and Paclitaxel were added at a fixed ratio determined by the 
respective GI50s for each compound and cell line. Cell viability was assayed 
after 5 days using the MTT reagent and calculations were done using the 
Compusyn program. 
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Meso Scale Discovery (MSD) assay 
In-house electrochemiluminescence (Meso Scale Discovery, MSD) assays 
were developed to measure tubulin acetylation and histone H3 
phosphorylation. After treatment, cells were washed with PBS and lysed with 
RIPA buffer (150mM NaCl, 50mM Tris pH 7.5, 1mM EDTA pH 8.0, 1% (v/v) 
NP40, 1% sodium deoxycholate, 0.1% SDS, 10mM NaF, protease inhibitor 
tablet, and phosphatase inhibitor cocktails) and sonicate briefly (3-4 pulses at 
mid power). Protein lysates were then diluted 1:10 in lysis buffer (50mM NaCl, 
20mM Tris pH 7.5, 1mM EDTA, 1mM EGTA, 1% (v/v) Triton X-100, 10mM 
NaF, protease inhibitor tablet and phosphatase inhibitor cocktails) to be 
compatible with the MSD buffer content required. For the acetylated tubulin 
MSD assay, 25μL of lysate (0.2-0.4µg/µl) was loaded onto MSD plates that 
were pre-coated with anti-tubulin antibody (1:100 in PBS, mouse monoclonal, 
Sigma, cat. no. 9026) and blocked with 3% (w/v) BSA, and protein lysates 
were incubated on the plate for 1h at room temperature on a shaker. Plates 
were with MSD wash buffer, and 25μL of anti-acetylated tubulin Antibody 
(rabbit polyclonal, Cell Signaling, cat. no. 5335) 1:100 diluted in 1% (w/v) BSA 
was added followed by incubation for a further 1h at RT. Plates were washed 
with MSD wash buffer and incubated with 25μL of anti-rabbit sulfo-TAG 
antibody (Meso Scale Discovery, cat. no. R32AB) diluted in 1% (w/v) BSA) for 
1h. After the final incubation, plates were washed with MSD wash buffer and 
read in the presence of 1xMSD read buffer. IC50 values were determined 
using GraphPad PRISM. For phosphorylated histone H3 MSD assay, the 
same preparation was used except that the plate was pre-coated with anti-
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pan histone antibody (2µg/ml diluted in PBS, mouse monoclonal, Millipore, 
cat. no. MAB3422) and anti-phospho histone H3 antibody (rabbit polyclonal, 
Millipore, cat. no. 06-570) 1:100 diluted in 1% (w/v) BSA was used to detect 
the phosphorylated Histone H3. 
Flow cytometry 
Flow cytometry to determine the cell cycle profile in HeLa cells after treatment 
with 100nM and 200nM BOS172722 for 24h, was performed as previously 
described (23).  
Metaphase spreads 
Cells were seeded in 10 cm dishes. The next day, Paclitaxel or 0.25% DMSO 
was added. After 36h, cells were arrested using nocodazole (100ng/ml) and 
further incubated for 4 hours. Mitotic cells were collected via mitotic shake off, 
pelleted, re-suspended in 0.75mM KCl and incubated at 37˚C for 8 minutes. 
After centrifugation, cells were fixed using a -20˚C solution of 4:1 
methanol:acetic acid. Cells were pelleted and fixative removed. 15l of cell 
suspension was dropped onto a glass slide and stained with 10g/ml DAPI. 
Pictures were taken on a Zeiss Imager.D1 microscope equipped with an 
AxioCam MRm using Axiovision software (Zeiss). 
Live cell imaging, immunofluorescence and immunoprecipitation 
Analysis by immunofluorescence and time lapse microscopy as well as 
immunoprecipitations were performed as previously described (7). 
Immunohistochemistry and immunofluorescence in human tumour 
xenografts 
Tumours were fixed in 10% neutral buffered formalin and embedded in 
paraffin. Phosphorylation of T875 on KNL1 was determined by 
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immunohistochemistry. Heat-based antigen retrieval was performed by boiling 
the 4-mm-thick tissue sections in pH=6 citrate buffer (TCS Biosciences Ltd., 
HDS05, 1:100 dilution) for 5 min in a pressure cooker. The sections were 
incubated with a rabbit polyclonal T875-KNL1 antibody for 2h and detected 
using a Vectastain Elite ABC kit (Vector Laboratories) and DAB reagent 
(Dako). Nuclei of the cells were located by counterstaining the sections with 
Harris’ haematoxylin. The T875-KNL1 antibody was generated by immunizing 
rabbits with phosphorylated peptides CNDMDI(pT)KSYTI (Eurogentec). T875-
KNL1 positive cells were quantified by manually counting positively stained 
cells in 8 random fields of the tumour section. Phosphorylation of Histone H3 
was determined by immunofluorescence. Heat-based antigen retrieval was 
performed as described above, except that the slides were heated in the 
microwave for 10 min. The sections were incubated with rabbit polyclonal p-
histone H3 (S10) antibody (Millipore, 06-570) for 1h, then incubated with 
secondary goat anti-rabbit IgG (H+L) Alexa Fluor 488 (Invitrogen, A-11034) 
and counterstained with DAPI. For each section, 9 fluorescent images were 
captured and quantification of p-Histone H3 positive cells was done in 
CellProfiler software (www.cellprofiler.org). 
Real-Time quantitative PCR 
RNA from cells was extracted using the Quick-RNA™ kit (Zymo Research) 
according to the manufacturer’s instructions. Real-time quantitative PCR 
reactions of the MPS1 gene were carried out using the TaqMan Universal 
PCR Master Mix (Applied Biosystems) in the Applied Biosystems StepOne-
plus Real-time PCR System, following the manufacturer's instructions.  We 
used commercially available primers and probes for PCR analyses (TaqMan 
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Gene Expression Assays, Assay ID: Hs01009870_m1 for MPS1, and 
Hs03003631_g1 for 18S and Hs04195421_s1 for PP1A as endogenous 
controls; Applied Biosystems). PCR conditions were as follows: 95°C for 10 
min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. Each 
sample was assayed in triplicate with RNase-free water as negative control. 
Relative gene expression quantifications were calculated according to the 
comparative Ct method using 18S or PP1A as an endogenous control. Final 
results were determined by the formula 2−ΔΔCt.  
In vivo efficacy studies 
The MDA-MB-468 and the OD-BRE-503 patient-derived xenograft studies 
were carried out at Oncodesign S.A., France. Statistical analyses of mean 
tumour volumes at randomisation were performed using ANOVA and pairwise 
tests were performed using the Bonferroni/Dunn correction in case of 
significant ANOVA results. A p-value < 0.05 was considered as significant. 
For the metastatic model, MDA-MB-231 luciferase-expressing cells were 
injected iv in the tails of NOD SCID mice. Mice were dosed starting 6 days 
after tumour cell implantation, with Paclitaxel at 15mg/kg on days 0 (day 0 is 
6th day after tumour cell implantation), 7, 14 and 21 i.v. and BOS172722 at 30 
and 40mg/kg p.o. on days 0+1, 7+8, 14+15 and 21+22 and tumour burden 
was assessed by whole body bioluminescent imaging (BLI). Animals were 
culled when they showed signs of deterioration due to tumour burden (body 
weight loss, rapid breathing). All animal studies were carried out in 
accordance with the UK Animals (Scientific Procedures) Act 1986 and 
national guidelines (35). 
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Results 
BOS172722 is a novel, potent and orally bioavailable MPS1 inhibitor in 
biochemical and cellular assays 
BOS172722 is a novel, orally bioavailable, potent and highly selective small 
molecule inhibitor of MPS1 kinase discovered from our in-house lead 
optimization studies on a pyridopyrimidine series of compounds (Figure 1A; 
(36).  In vitro kinase assays using purified recombinant MPS1 protein showed 
that BOS172722 inhibited MPS1 activity with IC50 values of 0.004µM at low 
ATP (10µM) and 0.01µM, at high (1mM) ATP concentrations respectively 
(Figure 1A). The in vitro profiling of BOS172722 was tested in a wide panel of 
more than 400 kinases (36). Only a small number of other kinases were 
inhibited by BOS172722, in particular JNK1, JNK2, JNK3 and LRRK2 at 
>80% at 1 μM.  Follow up IC50 values were obtained (JNK1 IC50 = 0.092µM, 
JNK2 IC50 = 0.076µM, JNK3 IC50 = 0.242µM and LRRK2 IC50 = 0.048µM) 
showing that BOS172722 is highly selective for MPS1 over these other 
kinases (36).  We have previously described the use of an in-house 
electrochemiluminescence (Meso Scale Discovery, MSD) assay to 
quantitatively measure MPS1 auto-phosphorylation in cells at T33/S37 sites 
(22,23). BOS172722 potently inhibited MPS1 T33/S37 auto-phosphorylation 
in MSD assay with IC50 value of 0.06 ± 0.03 µM (Figure 1A). To prove that the 
observed inhibition of MPS1 phosphorylation it is not a consequence of a 
mitotic exit, nocodazole-arrested HCT116 cells, a colon cancer cell line 
sensitive to MPS1 inhibition widely used for MPS1 activity investigation (20), 
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were co-treated with BOS172722 and MG132 proteasome inhibitor to block 
exit from mitosis, for 2h. Nocodazole-induced MPS1 auto-phosphorylation on 
T33/S37 was completely inhibited by treatment with BOS172722, indicating 
that BOS172722 specifically inhibits the activity of MPS1 (Figure 1B). Next, 
HCT116 cells treated with different concentrations of BOS172722 for 24 and 
48h were analysed for inhibition of histone H3 phosphorylation and PARP 
cleavage by immunoblotting. Histone H3 phosphorylation at Ser10 was 
inhibited in a time-dependent manner (Supplementary Figure S1A). Induction 
of apoptotic cell death upon drug treatment also increased as determined by 
levels of cleaved PARP (Supplementary Figure S1A). To identify the time that 
is required for BOS172722 to induce maximum effect on tumour cell growth 
inhibition, we performed wash-off experiments. HCT116 cells were treated 
with BOS172722 for 2 to 96h followed by the measurement of growth 
inhibition (GI50s) at 96h. We observed that 24h of treatment showed a 
comparable GI50 to 96h treatment (Supplementary Figure S1B), indicating that 
24h of MPS1 inhibition is sufficient to achieve maximum growth inhibition in 
tumour cells.  
 
Effects of BOS172722 on spindle assembly checkpoint activity and cell 
cycle 
MPS1 activity is required for activation of SAC and inhibition of its activity 
results in SAC override and mis-segregation of chromosomes. In order to 
investigate the mechanism of action of BOS172722, we performed live cell 
imaging of H2B-mCherry-transfected HeLa cells, a model widely used to 
study mitosis. We measured time in mitosis and chromosome segregation 
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defects after treatment with BOS172722. We found that treatment with 200nM 
of BOS172722 resulted in early mitotic exit of 11 minutes compared with 52 
minutes for the untreated HeLa cells (Figure 1C). This sharp decrease in time 
in mitosis resulted in gross chromosomal abnormalities including unaligned 
chromosomes (~83%) and decondensation of chromosomes without division 
(~17%; Figures 1D). In addition, induction of aneuploidy and loss of normal 
cell cycle profile was observed in cells treated with BOS172722 for 24 hrs with 
the indicated concentrations (Figure 1E). MPS1 activity is required for the 
recruitment of SAC components to the unattached kinetochores. To test this, 
HeLa cells were pre-treated with BOS172722 for 1 hour, then treated with 
nocodazole, MG132 and BOS172722 for an additional 1 hour to arrest the 
majority of cells in mitosis, followed by fixation and staining with the indicated 
antibodies (Supplementary Figure S1C). Treatment of cells with 200nM 
BOS172722 resulted in loss of recruitment of MAD1, MAD2, BUBR1, and 
KNL1 to the unattached kinetochores. A reduction in MPS1 T33/S37 auto-
phosphorylation was also observed with BOS172722 treatment, whereas 
MPS1 levels at kinetochores remained unchanged (Supplementary Figure 
S1C).  
 
Cell proliferation rate and SAC activity are important indicators for 
BOS172722 potency 
Prompted by the observation that PTEN-deficient cell lines are more sensitive 
to MPS1 inhibition (37) and in order to identify additional populations that may 
benefit from an MPS1 inhibitor, we tested 50 cancer cell lines, including 25 
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PTEN-proficient and 25 PTEN-deficient, with BOS172722 in a 5-day growth 
inhibition assay (Supplementary Table S1A). The results showed that, 
although there is a clear trend in sensitivity to MPS1 inhibition with 
BOS172722 between PTEN-deficient and PTEN-proficient cell lines, the 
difference was not statistically significant (Figure 2A). Treatment of 50 cancer 
cell lines from 8 different tissues of origin, in addition to the data we have 
generated using TNBC cell lines, showed that lung cancer cell lines overall 
show similarly sensitivity to MPS1 inhibition (Supplementary Figure S2A). In 
addition, similar to TNBC cell lines, the average doubling time of the cell lines 
above the median GI50 was higher than the average doubling time of the cell 
lines below the median GI50. Moreover, there was a statistically significant 
difference between the doubling time of the most sensitive cell lines (top 
tercile, n=17, 38 hrs) relative to the rest of the cell lines (n=33, 53 hrs; Figure 
2B), suggesting that more rapidly dividing cells show greater susceptibility to 
MPS1 inhibition. Towards the identification of mutations that could predict 
sensitivity to BOS172722, we extracted non-silent mutations in the coding 
regions of genes for 16 sensitive cell lines (GI50 < 50nM) and 16 resistant cell 
lines (GI50 > 200nM) from the Cancer Cell Line Encyclopaedia (CCLE) 
database and looked for enrichment of mutated genes in the sensitive group. 
We selected genes that were mutated in at least 3 cell lines in the sensitive 
group over the resistant group and in no more than two cell lines in the 
resistant group and calculated the fold enrichment in the two sets 
(Supplementary Table S1B). The most enriched mutated gene in the sensitive 
group was PI4KB, a protein that has been shown to be active in mitosis (38) 
and to prevent formation of polylobed nuclei (39) which is indicative of mitotic 
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exit with aberrant chromosome segregation and aneuploidy (Figure 2C). 
Similarly, mutations in ARID1A and SMARCA4 have been shown to induce 
genomic instability and aneuploidy (40) that is further increased to intolerable 
levels by MPS1 inhibition, resulting in cell death. In addition, mutations in 
NUMA1 and TPR, that have been shown to be involved in mitotic spindle 
assembly and in the activation of the SAC (41-43), may directly sensitise cells 
to MPS1 inhibition. 
We have previously shown that basal breast cancer cell lines (including 
TNBC) were more sensitive to our tool compound MPS1 inhibitor CCT271850 
in comparison to luminal breast cancer cell lines (23). To investigate further, 
we used a panel of TNBC and non-TNBC cell lines to investigate the 
association between the potency of BOS172722 to: a) TNBC versus non-
TNBC cell lines; b) MPS1 expression; c) proliferation rate and d) SAC activity. 
We confirmed that TNBC cell lines are more sensitive to BOS172722 in 
comparison with non-TNBC cell lines (Supplementary Figure S2B and 
Supplementary Table S2). Our data from breast cancer cell lines are in 
agreement to the published data from primary breast tumours (44) that MPS1 
expression is higher in TNBC versus non-TNBC cell lines (Supplementary 
Figures S2C,D). Importantly, we found that the cellular potency of 
BOS172722 at Emax (representing maximum effect) significantly associated 
with the proliferation rate of the cell lines as measured by their doubling times 
(Figure 2D), similar to the panel of the 50 cell lines from different types of 
human cancers described above (Figure 2B); TNBC cell lines, being more 
sensitive, have shorter doubling times (Supplementary Figure S2E). We then 
investigated the association between BOS172722 potency and levels of SAC 
 
 
15 
activity. To our surprise, cell lines with reduced SAC activity, as measured by 
MPS1 phosphorylation and BUB1 localisation upon mitotic arrest, were more 
sensitive to BOS172722 treatment (Figures 2E,F, Supplementary Table S2), 
indicating that cell lines with a compromised SAC may require lower doses of 
an MPS1 inhibitor to abrogate the mitotic checkpoint, thereby inducing gross 
chromosomal abnormalities and cell death. TNBC cell lines overall showed an 
overall weaker SAC. A t-test or a one-way ANOVA, shows p-value <0.009. 
However, we used the u-test as these data failed to pass the Shapiro-Wilk 
normality test. Based on u-test, TNBC cells have on average lower 
pMPS1/mitotic index ratios (mean 4.75, standard deviation 2.31) relative to 
non-TNBC cells (mean 32.5, standard deviation 21.6), including two extreme 
non-TNBC outliers with ratios of 1.1 and 2.2. However, although low ratios 
may be found in other populations, TNBC cells represent a homogenous 
group. These data together suggest that the proliferation rate together with 
the SAC activity may potentially be used as stratification markers for TNBC 
patient selection to achieve maximum efficacy. 
 
BOS172722 shows synergistic effect with paclitaxel in TNBC cell lines 
Based on its promising in vitro profile, we progressed BOS172722, to human 
tumour xenograft models of TNBC to initially evaluate single agent efficacy. In 
established orthotopic MDA-MB-231 xenografts, BOS172722 given at 
50mg/kg orally, twice a week for 47 days showed significant but moderate 
reduction of tumour growth compared with vehicle-treated mice (tumour 
growth inhibition: TGI = 66%, p = 0.0001; Supplementary Figure S3). 
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However, to support clinical trials as a single agent would require evidence of 
tumour stasis or regression in preclinical models. We therefore screened a 
panel of TNBC cell lines for synergism between BOS172722 with paclitaxel 
(Tax) at 1 and 2nM, doxorubicin (Dox) at 2 and 4nM and eribulin (Eri) at 0.1 
and 0.2nM, to a wide range of BOS172722 concentrations (0 to 500nM). The 
data were then analysed using MacSynergyII (45). Of the combinations of 
compounds tested, only paclitaxel with BOS172722 showed consistent 
synergy across our panel of TNBC cell lines (Figure 3A). By contrast, 
treatment of BOS172722 together with eribulin or doxorubicin did not show 
any synergy in the majority of the cell lines tested, with few exceptions (Figure 
3A). We therefore focused on further characterising the mechanism of the 
synergism between BOS172722 and paclitaxel. In our screen, we used 
concentrations of 1 and 2nM of paclitaxel and the maximum synergism was 
observed at 1nM or <2nM for all cell lines (Supplementary Table S3).  
Importantly, the observed synergistic concentrations were relevant to the 
clinical concentrations of paclitaxel (46). In addition, the paclitaxel 
concentrations where maximum synergy is observed are either at or below 
the respective GI50s of paclitaxel alone and are related to clinical dosing 
schedules (46) (Supplementary Table S3).  
 
In order to investigate the mechanism of action of the synergism of paclitaxel 
with BOS172722, we performed flow cytometry analysis of the cell cycle of 
MDA-MB-231 after treatment with each drug individually or in combination. 
Treatment of MDA-MB-231 cells with 1nM paclitaxel or 100nM BOS172722 
for 24h did not show any significant cell cycle effect on the cells. However, the 
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combination of both agents led to a pronounced decrease in height and 
broadening of the G1 cell cycle peak, consistent with the induction of 
aneuploidy (Figure 3B). At these drug concentrations the cell cycle profile was 
completely abolished (an expected minor effect on the cell cycle histogram 
was observed at 2nM paclitaxel alone; Figure 3B).  
  
MPS1 inhibition reduces paclitaxel-induced mitotic delay and 
potentiates gross chromosome mis-segregation errors  
The therapeutic effect of paclitaxel had long been attributed to the induction of 
a mitotic arrest (activating the SAC), resulting in cell death. Recent work 
however, demonstrated that paclitaxel exerts its effect mainly by the induction 
of aneuploidy via a multipolar mitosis (46). In contrast, MPS1 inhibition leads 
to premature abrogation of the SAC and as a consequence, detrimental 
aneuploidy (7).  
 
We first assessed the abrogation of mitotic checkpoint by each drug, both 
individually and in combination using live cell microscopy of HeLa cells. 
Incubation of cells with BOS172722 resulted in a dose-dependent decrease in 
the median length of time cells spent in mitosis (Figure 3C). In order to 
measure the type and the magnitude of the chromosomal damage induced by 
combining BOS172722 and paclitaxel, we performed live cell imaging of H2B-
mCherry transfected HeLa cells. We could thereby quantify chromosome 
segregation errors induced by the single agents and their combinations. As 
seen in Figure 3D, paclitaxel or BOS172722 at low concentrations alone 
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induce minor mitotic abnormalities. At higher concentrations of the individual 
drugs, the drug inherent phenotypes were evident: paclitaxel induces mainly 
multipolar mitotic figures in contrast to BOS172722, which predominantly 
induced division with unaligned chromosomes. In the case of the combination 
of both drugs, the number of abnormal mitosis which mainly exhibit unaligned 
chromosomes is synergistically increased. Importantly, even at 1nM 
concentration of paclitaxel, where the highest synergy scores were observed 
in our screen of growth inhibition, it induces only low levels of aneuploidy. We 
confirmed this result in MDA-MB-231 cells using metaphase spreads 
(Supplementary Figure S4A). Since both MPS1 inhibition and paclitaxel 
treatment cause chromosome alignment errors, we reasoned that the synergy 
between paclitaxel and BOS172722 may arise through increasing the amount 
of erroneous MT-kinetochore attachments. Indeed, using 
immunofluorescence-based assays, the amount of chromosome alignment 
errors increased following combination of the drugs, only additively, in all 
tested combinations, when mitotic exit was prevented with MG132 
(Supplementary Figure S4B,C). 
 
Paclitaxel induces a weak mitotic checkpoint delay  
Because we did not observe consistent synergy with eribulin in our initial 
screen, we then investigated whether a SAC which has been activated to the 
same extent by MT-depolymerizing or whether MT-stabilizing drugs shows a 
differential response to MPS1 inhibition. In order to achieve comparable 
checkpoint activation with microtubule depolymerizing and stabilizing agents, 
we treated HeLa cells with nocodazole or paclitaxel and determined the 
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concentration at which maximal activation of the checkpoint was achieved as 
observed by a plateau in mitotic timing. Cells were then arrested for 16h with 
the respective MT poisons, different doses of BOS172722 added and the 
fraction of cells in mitosis measured. Of note, treatment with the respective 
concentrations of nocodazole or paclitaxel alone led to a very similar duration 
of the time cells remained arrested in mitosis (Figure 4A). In both cases, the 
mitotic block was overcome by MPS1 inhibition but, markedly, in paclitaxel 
arrested cells, this override was achieved with much lower concentrations of 
BOS172722 compared with nocodazole. A comparable rate of mitotic exit was 
achieved with 25nM BOS172722 in paclitaxel-arrested cells and 100nM 
BOS172722 (4 times the concentration) in nocodazole-arrested cells. We 
therefore considered that the maximal SAC induced by microtubule 
depolymerizing agents is comparably stronger than the analogous SAC 
induced by paclitaxel. In line with this hypothesis, when we analysed the 
recruitment of BUB1 to the kinetochore by immunofluorescence, BUB1 levels 
were, on average markedly lower in the cells arrested with paclitaxel, being on 
average 50% of the levels seen in nocodazole and with a much larger range 
(Figure 4B). Taken together, these data, suggest that the override of the weak 
paclitaxel-induced SAC with low concentrations of BOS172722 may explain 
the synergistic increase in cell death.  
 
Simultaneous combination of BOS172722 with paclitaxel for 24h induces 
maximum synergy  
In order to better delineate the time that is required for the combination of 
paclitaxel and BOS172722 to exert a synergistic effect, we incubated MDA-
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MB-231 cells with BOS172722 for distinct periods of time and analysed the 
induced synergism with paclitaxel. We observed that incubation of both drugs 
for 12h had only a limited synergistic effect in MDA-MB-231 cells 
(Supplementary Figure S4D). We then explored the synergy of paclitaxel and 
BOS172722 in association with the incubation time in wash-off long-term 
clonogenic assays in MDA-MB-231 cells. We found that the combination of 
1nM paclitaxel with 10nM BOS172722 was as efficacious as higher 
concentrations of each individual drug (Figure 4C). We were also interested in 
investigating whether sequential addition of the drugs had any benefit over 
simultaneous treatment on the degree of synergism seen. The addition of 
BOS172722 following paclitaxel treatment or the opposite, had no superior 
effect over the simultaneous addition (Supplementary Figure S4E). Therefore, 
simultaneous administration of drugs is potentially the most beneficial in 
clinical studies. Based on our data we propose the following model (Figure 
4D): treatment with Paclitaxel induces mitotic arrest with unaligned 
chromosomes due to impaired microtubule dynamics and partial inactivation 
of the SAC due to the presence of kinetochore-microtubule attachments in 
some chromosomes. Cancer cells can escape mitotic arrest by mitotic 
slippage and/or following metabolism/excretion of the drug. Not all cells will 
have lethal levels of chromosomal abnormalities. Treatment with Paclitaxel in 
combination with BOS172722 completely prevents chromosome alignment in 
cancer cells due to impaired microtubule dynamics and dramatically reduced 
time in mitosis. All cells exit mitosis with gross chromosomal abnormalities 
and are not viable. 
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In vivo pharmacodynamic activity of BOS172722 
In pharmacodynamic (PD) experiments in vivo BOS172722 potently inhibits 
the SAC induced by paclitaxel in human tumour xenograft models of TNBC 
(MDA-MB-231), as measured by inhibition of the mitotic marker 
phosphorylated histone H3 (p-HH3) by immunofluorescence microscopy 
(Figure 5A right graph and 5B lower panel). We confirmed that this effect is 
mediated by MPS1 inhibition by demonstrating reduction of the mechanism-
related proximal biomarker phosphorylated-KNL1 (p-KNL1) by 
immunohistochemistry (IHC; Figure 5A left graph and 5B upper panel). KNL1 
is a natural substrate of MPS1 and is phosphorylated upon initiation of SAC 
activation by MPS1 (47).  
 
Having shown that BOS172722 abrogates SAC as measured by paclitaxel-
induced p-HH3 and p-KNL1 inhibition, we investigated whether we could 
identify target-engagement biomarkers to measure the activity of both 
paclitaxel and BOS172722 simultaneously in the same samples. It is known 
that taxanes induce acetylation of tubulin due to tubulin polymerisation (48), 
when at the same time MPS1 inhibition should not affect tubulin modification. 
Paclitaxel and BOS172722 was administrated simultaneously into HCT116 
tumour bearing mice. Figure 5C shows paclitaxel-induced acetylation of 
tubulin at all time points while addition of BOS172722 had no effect on tubulin 
acetylation. In contrast, paclitaxel-induced histone H3 phosphorylation was 
significantly inhibited by BOS172722 at 2 and 6h. To optimise these assays in 
a high throughput format, we developed quantitative 
electrochemiluminescence assays (MSD). The results confirmed the 
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immunoblotting data, indicating a potential use of these biomarkers in the 
clinic (Figure 5D). 
 
Therapeutic activity of BOS172722 in in vivo TNBC models 
Based on in vitro activity and PD data, human TNBC xenograft experiments in 
athymic mice were undertaken to evaluate the therapeutic activity of paclitaxel 
alone or in combination with BOS172722. We initially used an MDA-MB-468 
orthotopic (mouse mammary fat pad) xenograft model. Combination of 
BOS172722 with paclitaxel gave significant tumour regressions and a clear 
benefit in comparison with paclitaxel alone (Figure 6A). A study using a TNBC 
patient-derived xenograft (PDX) model also showed tumour regression and a 
significant benefit of combination treatment in comparison with paclitaxel 
alone (Figure 6B).  
 
We then performed in vivo studies using a TNBC model to simulate breast 
cancer metastases. Tail-vein-injected MDA-MB-231-luciferase-expressing 
TNBC cells in SCID mice give rise predominantly to lung metastases.  On day 
28, the flux expressed as % of vehicle control was as follows: paclitaxel alone 
18.8%; combination with BOS172722 at 30mg/kg 4.8% and 40mg/kg 5.7% 
confirming a significant benefit of combination treatment in both tumour 
growth and survival (up to day 63) at BOS172722 doses ≥ 30mg/kg (Figure 
6C,D). Taken together, the data described above demonstrate that our 
selective MPS1 inhibitor BOS172722 in combination with paclitaxel 
synergistically induces increased cell death in TNBC cell lines in vitro and 
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regression and/or reduced growth rate of human tumour xenografts in vivo 
compared to treatment with either agent alone. 
 
Discussion 
We initially discovered MPS1 as a potential therapeutic target during a siRNA 
screening campaign where we showed that a subgroup of breast cancer cell 
lines with a deregulated PTEN tumour suppressor gene were susceptible to 
cell death upon MPS1 depletion (37). We further investigated these findings 
using BOS172722. Fifty cell lines, 25 PTEN-proficient and 25 PTEN-deficient 
from a variety of human cancer types were tested upon treatment with 
BOS172722. We found a clear trend of sensitivity to BOS172722 of cell lines 
with PTEN deficiency, irrespective of the type of cancer. Although not 
statistically significant, patients with PTEN deficient tumours may represent a 
target population for treatment with an MPS1 inhibitor.  However, the 
strongest, statistically significant corollary of sensitivity to MPS1 inhibition was 
cell proliferation rate. Cells with shorter doubling times were more sensitive to 
death upon MPS1 inhibition, TNBC cell lines being the most sensitive. A novel 
indicator for sensitivity to MPS1 inhibition is the SAC activity. We found that 
cell lines with reduced SAC activity were more sensitive to BOS172722, 
suggesting that lower SAC activity requires reduced concentrations of the 
MPS1 inhibitor to abrogate mitosis, thus inducing detrimental aneuploidy in 
cancer cells.  
 
Due to the moderate levels of tumour growth inhibition by BOS172722 in 
xenograft studies, we focused on combination studies with the standard-of-
 
 
24 
care agents in TNBC. We identified paclitaxel as a favourable combination 
agent for use with MPS1 inhibition as it exerts robust synergistic effects 
throughout our panel of TNBC cell lines. This combination has also been 
identified by others and clinical trials have been initialized (19,49; 
NCT02366949). Importantly, we discovered that a reduced SAC checkpoint is 
easier to override with an MPS1 inhibitor.  
The same MPS1 mechanism of action is observed in paclitaxel-treated human 
TNBC xenografts in vivo. Athymic mice carrying TNBC human tumour 
xenografts were treated with vehicle, paclitaxel alone at clinically relevant 
dose or in combination with single dose BOS172722. Immunofluorescence 
microscopy and immunohistochemistry of tumour sections showed a 
significant reduction of phospho-histone H3 and reduction of phospho-KNL1. 
These data confirm the mechanistic contribution of MPS1 inhibition in vivo. In 
addition, we have suggested a novel target engagement biomarker strategy to 
be able to measure simultaneously the effect of paclitaxel and BOS172722 in 
tumour biopsies. The therapeutic benefit of BOS172722 in combination with 
paclitaxel was demonstrated in three TNBC in vivo models: MDA-MB-468 
orthotopically transplanted in mouse mammary fat pads, systemic metastatic 
MDA-MB-231 and in a TNBC patient derived xenograft. 
 
In summary, BOS172722 is a highly potent and selective, orally bioavailable 
MPS1 inhibitor with favourable PK. Robust efficacy was demonstrated at well 
tolerated doses in combination with paclitaxel in multiple xenograft models of 
TNBC, including PDX. BOS172722 is now in Phase I dose escalation clinical 
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trials in combination with standard of care paclitaxel treatment 
(NCT03328494). 
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Figures 
 
Figure 1. BOS172722 structure and characterization in biochemical and 
cellular assays. A.  Structure and biochemical and cellular activity of 
BOS172722. B. Myc-MPS1-expressed nocodazole-arrested HCT116 cells 
treated with BOS172722 were tested for MPS1 inhibition. Background band 
was used as loading control. C. Box-and-whisker plot showing the time of 
HeLa cells in mitosis, in the absence or presence of BOS172722. The result 
was analyzed by Student‘s t-test (p < 0.0001). N = 66 cells per condition. D. 
Bar graph quantifying mitotic defects in HeLa cells treated with BOS172722. 
E. Flow cytometry cell-cycle profiles of HeLa cells treated with BOS172722.  
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Figure 2. Association of BOS172722 in vitro potency with PTEN status, 
proliferation rate and SAC activity.  A. Average GI50 of PTEN deficient 
(PTEN-) and PTEN proficient (PTEN+) cell lines. Bars represent standard 
error, p-value represents a two-tailed Student’s t-test. B. Average doubling 
time for the top tercile of most sensitive cell lines versus the rest of the cell 
lines from the Horizon dataset. Bars represent standard error, p-value 
represents a two-tailed Student’s t-test. C. Heatmap of mutated genes in cell 
lines with GI50 < 50nM (SENSITIVE) and > 200nM (RESISTANT). Dark 
squares are indicating the cell line with the corresponding mutated gene. D. 
Non-parametric Spearman correlation of Emax was measured by treatment of 
BOS172722 and doubling time in TNBC (black dots) and non-TNBC cell lines 
(white dots and triagles). White triangles in non-TNBC group indicate HER2 
positive and overexpressed cell lines. The p-value is two-tailed and dot lines 
indicate 95% confidence interval of Spearman correlation. E. Scatter dot plot 
of the ratio of pT33pS37-MPS1 over mitotic index in TNBC and non-TNBC 
cell lines after Paclitaxel treatment. p-value represents a two-tailed Mann 
Whitney test. F. Scatter dot plot of the median ratio of BUB1 over ACA 
fluorescent signal in the kinetochore of TNBC and non-TNBC cell lines after 
Paclitaxel treatment. p-value represents a two-tailed Mann Whitney test.  
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Figure 3. Synergy of BOS172722 with standard-of-care drugs in TNBC 
cell lines and mechanistic studies. A. Bar chart of synergism volumes of 
BOS172722 with Paclitaxel, Eribulin and Doxorubicin in TNBC cell lines. B. 
FACS analysis of the cell cycle distribution in MDA-MB-231 cells after 24h 
incubation with indicated drugs. C. Evaluation of the SAC in response to 
treatment with Paclitaxel and BOS172722. Hela cells were incubated with 
Paclitaxel, BOS172722 or a combination of both. Mitotic timing was then 
assayed by live cell imaging as the time from nuclear envelope breakdown 
until the start of anaphase. Box plots show median, 25th to 75th percentile and 
min/max values. D. Hela cells, stably transfected with H2B-mCherry, were 
treated with the indicated compounds. >60 cells were analysed for each 
condition. The graph depicts the quantification of chromosome alignment 
errors as measured by live cell imaging.  
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Figure 4. SAC respond to microtubule stabilising and destabilising 
drugs. A. Comparison of SAC override by BOS172722 between Paclitaxel 
and nocodazole treated Hela cells. Plotted is the fraction of cells in mitosis at 
any given time. Only cells already arrested at the start of time-lapse imaging 
are included in the analysis with BOS172722 added to the cells at 0 minute. 
B. Quantification of BUB1 accumulation at centromeres in nocodazole and 
Paclitaxel-treated cells. Measurements were done in triplicate. C. Long-term 
proliferation assay. MDA-MB-231 cells were incubated with BOS172722, 
Paclitaxel and the combination of both for 24h. Whole cell growth was 
determined by SRB after 14 days. D. Model of the mechanism of synergism 
between BOS172722 and Paclitaxel. 
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Figure 5. In vivo Pharmacodynamic studies of BOS172722. A, 
Pharmacodynamic analyses of Paclitaxel and BOS172722 in MDA-MB-231 
subcutaneous human tumour xenografts. Vehicle, Paclitaxel alone and the 
simultaneous combination of Paclitaxel + BOS172722. Percentage of 
phospho-Histone H3 (p-HH3) positive cells by immunofluorescence and p-
KNL1 by immunohistochemistry staining at 8h after treatment. B. 
Representative images of staining at 8h after treatment. C. Immunoblot 
analysis of tumour lysates from HCT116 xenografts in athymic mice treated 
with vehicle (V), Paclitaxel alone (P) or Paclitaxel in combination with 
BOS172722 (C). Antibodies against acetylated and total tubulin, 
phosphorylated and total histone H3 were used at the indicated time points. 
D. MSD assays to measure the level of acetylated tubulin and phosphorylated 
Histone H3 in HCT116 xenografts.  
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Figure 6.  In vivo therapeutic activity of BOS172722 in TNBC models. A. 
Tumour volumes were plotted-out to day 35 from the start of treatment when 
all cohorts were >80% complete. Arrows represent Paclitaxel treatment days; 
***: 2-way RM ANOVA p<0.0001. B. Tumour volumes were plotted out to day 
43 from the start of treatment when all cohorts were >80% complete. Arrows 
represent Paclitaxel treatment days; ***: 2-way RM ANOVA p<0.0001. C. 
Metastasis model of MDA-MB-231 luciferase-expressing tumours in NOD 
SCID mice. On day 28, the flux in the treated groups (mean total flux ± SEM) 
is indicated. D, Survival curves until day 63. 
 
